bpr

Bromophenol red (BPR) is a chemical indicator. It has been shown to bind to lysozymes and inhibits their activity against bacterial cell walls, but not against the polysaccharide component of peptidoglycan.

BPR1M97 是一种具有血脑屏障渗透性和有效性的 mu 阿片受体（MOP）和神经肽-啡肽 FQ（NOP）受体激动剂，对 MOP 的 Kis 值为1.8 nM，对 NOP 的Kis 值为 4.2 nM。BPR1M97 具有抗伤害作用和抗痛觉作用。

BPR1K871 (DBPR114) 是一种高效选择性的 FLT3 AURKA 双重抑制剂，对 FLT3 和 AURKA 作用的 IC50值分别为 19 nM 和 22 nM。BPR1K871 具有抗癌治疗的潜力。

BPR0L075 [6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole] 为一种抗微管化合物，具备抗癌活性，并显示出抗有丝分裂功能。

BPR1-J097 是新型的、强效的FLT3抑制剂 (IC50:11 nM)。

BPR1R024 is an orally active and selective CSF1R inhibitor ( IC 50 = 0.53 nM).

BPR1J-097 hydrochloride (1327167-19-0(free base)) 是一种新型小分子 FLT-3抑制剂(IC50=11±7 nM)，具有很好的体内抗肿瘤活性。

BPR1J-340 is a potent and selective FLT3 inhibitor with potential anticancer activity. BPR1J-340 was identified as a novel potent FLT3 inhibitor by biochemical kinase activity (IC50 approximately 25 nM) and cellular proliferation (GC50 approximately 5 nM) assays. BPR1J-340 inhibited the phosphorylation of FLT3 and STAT5 and triggered apoptosis in FLT3-ITD(+) AML cells. The pharmacokinetic parameters of BPR1J-340 in rats were determined. BPR1J-340 also demonstrated pronounced tumor growth inhibition and regression in FLT3-ITD(+) AML murine xenograft models. The combination treatment of the HDAC inhibitor vorinostat (SAHA) with BPR1J-340 synergistically induced apoptosis via Mcl-1 down-regulation in MOLM-13 AML cells, indicating that the combination of selective FLT3 kinase inhibitors and HDAC inhibitors could exhibit clinical benefit in AML therapy.

BPR1K653 is a potent Aurora kinase inhibitor with potential anticancder activity. BPR1K653 specifically inhibited the activity of Aurora-A and Aurora-B kinase at low nano-molar concentrations in vitro. BPR1K653 was potent in targeting a variety of cancer cell lines regardless of the tissue origin, p53 status, or expression of MDR1. At the cellular level, BPR1K653 induced endo-replication and subsequent apoptosis in both MDR1-negative and MDR1-positive cancer cells. Importantly, it showed potent activity against the growth of xenograft tumors of the human cervical carcinoma KB and KB-derived MDR1-positive KB-VIN10 cells in nude mice. Finally, BPR1K653 also exhibited favorable pharmacokinetic properties in rats., BPR1K653 is a promising anti-cancer compound that has potential for the management of various malignancies, particularly for patients with MDR1-related drug resistance after prolonged chemotherapeutic treatments.

BPR3P0128是一种口服活性非核苷类RNA依赖性RNA聚合酶 (RdRp) 抑制剂，可抑制各种SARS-CoV-2变异体活性，对SARS-CoV-2和HCoV-229E的EC50分别为0.62和0.14 µM，在亚微摩尔范围内具有高效抗泛冠状病毒活性，并与Remdesivir联用表现出协同抗病毒活性。

BPR5K230 作为MER和AXL受体酪氨酸激酶的双重抑制剂，分别展示了4.1 nM和9.2 nM的IC50。该化合物还能抑制Ba F3-MER细胞的增殖，具体IC50达到5 nM。在小鼠体内，BPR5K230展现出优秀的药代动力学属性，并在4T1、MDA-MB-231、MC38和Hepa1-6小鼠模型中显示了抗炎及抗肿瘤活性。

FPL-63012AR is a D1-receptor agonist.

DBPR112 是一种口服有效的基于氟嘧啶的 EGFR 抑制剂，对 EGFRWT 和 EGFRL858R T790M 的 IC50 分别为 15 nM 和 48 nM。DBPR112 可以占据 ATP 结合位点。DBPR112 具有显着的抗肿瘤功效。

DBPR108是新型、具有口服活性、选择性的DPP4抑制剂，IC50=为15nM，对DPP8和DPP9基本无抑制。

BPRMU191, 一种独特的mu-opioid受体（MOR）调节剂，在CHO-K1 MOR Gα15细胞的FLIPR Ca2+检测中，其EC50为2.17 uM。此外，BPRMU191在纳洛酮存在时与MOR结合。

DBPR116 是一种能够穿透血脑屏障的BPRMU191前药。它显著增强了中枢靶向药物的递送能力。DBPR116 与拮抗剂Naltrexone 联合使用时，在多种体内药理学研究中（包括热痛模型、癌痛模型、便秘、镇静、心理依赖、心率和呼吸频率等）展示出比吗啡更优越的安全性和镇痛效果。作为一种外周给药的前药策略，DBPR116 在有效缓解疼痛的同时减少不良反应，有望成为更安全的阿片类镇痛药。

DBPR-110 is a nonstructural protein 5A (NS5A) inhibitor. DBPR-110 reduced the reporter expression of the HCV1b replicon with a EC(50) and a selective index value of 3.9 ± 0.9 pM and >12,800,000, respectively. DBPR-110 reduced HCV2a replicon activity with

DBPR112 is a potent EGFR inhibitor (IC50=487 nM) as a Clinical Candidate for the Treatment of Non-Small Cell Lung Cancer. DBPR112), DBPR112 not only displayed a potent inhibitory activity against EGFRL858R T790M double mutations but also exhibited tenfold potency better than the third-generation inhibitor, osimertinib,against EGFR and HER2 exon 20 insertion mutations. Overall, pharmacokinetic improvement through lead-to-candidate optimization yielded fourfold oral AUC better that afatinib along with F = 41.5%, an encouraging safety profile, and significant antitumor efficacy in in vivo xenograft models.

IBPR002 is an aurora kinase inhibitor which reveals mechanisms of HURP in nucleation of centrosomal and kinetochore microtubules.

DBPR728 是 6K465 的酰基前药，包含较少的氢键供体，作为 Aurora 激酶抑制剂，6K465 能破坏 MYC 家族癌蛋白的稳定性，显示出抗肿瘤作用。DBPR728 可能抑制过表达 C-MYC 和 N-MYC 的癌症，其口服生物利用度相比 6K465 提高了 10 倍。

5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid 为舒尼替尼杂质。

Benzyl b-primeveroside 是一种有用的有机化合物，可用于生命科学领域的相关研究。其产品编号为 T126071，CAS号为 130622-31-0。

Palbociclib-propargyl, a PROTAC ligand targeting the protein CDK6, connects to the CRBN ligand through a PEG linker to form PROTAC CP-10. CP-10 exhibits a potent DC50 value of 2.1 nM against CDK6[1].

6-OH-BTA-0 (11C-PiB Precursor) 是一种合成农药的中间体，是 6-OH-BTA-1 的前体，可用于合成 β-淀粉样蛋白显像剂。